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Abstract
Purpose Inflammation and neovascularization in vulnerable
atherosclerotic plaques are key features for severe clinical
events. Dynamic contrast-enhanced (DCE) MRI and FDG
PET are two noninvasive imaging techniques capable of
quantifying plaque neovascularization and inflammatory infil-
trate, respectively. However, their mutual role in defining plaque
vulnerability and their possible overlap has not been thoroughly
investigated. We studied the relationship between DCE-MRI
and 18F-FDG PET data from the carotid arteries of 40 subjects
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with coronary heart disease (CHD) or CHD risk equivalent, as a
substudy of the dal-PLAQUE trial (NCT00655473).
Methods The dal-PLAQUE trial was a multicenter study that
evaluated dalcetrapib, a cholesteryl ester transfer protein mod-
ulator. Subjects underwent anatomical MRI, DCE-MRI and
18F-FDG PET. Only baseline imaging and biomarker data
(before randomization) from dal-PLAQUE were used as part
of this substudy. Our primary goal was to evaluate the rela-
tionship between DCE-MRI and 18F-FDG PET data. As sec-
ondary endpoints, we evaluated the relationship between (a)
PET data and whole-vessel anatomical MRI data, and (b)
DCE-MRI and matching anatomical MRI data. All correla-
tions were estimated using a mixed linear model.
Results We found a significant inverse relationship between
several perfusion indices by DCE-MRI and 18F-FDG uptake by
PET. Regarding our secondary endpoints, there was a significant
relationship between plaque burdenmeasured by anatomicalMRI
with several perfusion indices byDCE-MRI and 18F-FDG uptake
by PET. No relationship was found between plaque composition
by anatomical MRI and DCE-MRI or 18F-FDG PET metrics.
Conclusion In this study we observed a significant, weak in-
verse relationship between inflammation measured as 18F-FDG
uptake by PET and plaque perfusion by DCE-MRI. Our find-
ings suggest that there may be a complex relationship between
plaque inflammation and microvascularization during the dif-
ferent stages of plaque development. 18F-FDG PET and DCE-
MRI may have complementary roles in future clinical practice
in identifying subjects at high risk of cardiovascular events.
Keywords DCE-MRI . PET/CT . Atherosclerosis .
Inflammation . Neovascularization
Introduction
In recent years, significant progress has been made in defining
the hallmarks of high-risk, vulnerable atherosclerotic plaques.
Vulnerable atheromas are characterized by a large lipid-rich
necrotic core (LRNC), thin fibrous cap and prominent inflam-
matory infiltrate accompanied by abundant and fragile
neovessels [1]. This knowledge has stimulated the development
of novel, noninvasive imaging techniques to identify vulnerable
plaques, with the aim of improving risk stratification, follow-up
and management of therapeutic intervention by directly
preventing acute events [2]. Techniques such as non-contrast-
enhanced, anatomical MRI, CT and ultrasonography can quan-
tify anatomical characteristics and detect key components of
vulnerable plaques. Other techniques can extract quantitative
information about molecular mechanisms within the plaque.
18F-FDG PET with CT and dynamic contrast-enhanced (DCE)
MRI allow measurement of inflammation [3–5] and
neovascularization [6–9], respectively, two features of plaque
vulnerability. Both techniques show reasonable reproducibility
[5, 10] and have been used to track antiatherosclerotic therapies
in both clinical and preclinical trials [11–16]. However, the
possible degree of overlap of the information provided by each
test has not been thoroughly investigated. In this study, we
investigated the relationship between 18F-FDG PET/CT and
DCE-MRI data from the common carotid arteries of 40 subjects
with either coronary heart disease (CHD) or CHD risk factors
(CHD risk equivalent) recruited as part of the dal-PLAQUE
multicenter trial (NCT00655473) [14, 15].
Methods
Study design
This study was conducted as part of the dal-PLAQUE multi-
center trial that evaluated dalcetrapib, a cholesteryl ester trans-
fer protein modulator [14, 15]. The protocol was reviewed and
approved by the institutional review board of each participat-
ing center. Each participating center was trained in the image
acquisition protocol by the core laboratory for image analysis
of the dal-PLAQUE trial (Icahn School of Medicine at Mount
Sinai, New York, NY). All participants provided written in-
formed consent. Here we report only baseline (prior to ran-
domization) anatomical MRI, DCE-MRI, 18F-FDG PET/CT
and biomarker data from the dal-PLAQUE study.
Study population
The study population of dal-PLAQUE comprised patients with
CHD or CHD risk equivalent. Patients were clinically stable
and receiving appropriate treatment with a statin and/or other
drugs for lowering low-density lipoprotein cholesterol (LDL-
C) to achieve LDL-C levels of <100 mg/dL (<2.6 mmol/L),
unless receiving maximum tolerated doses of therapy or intol-
erant to statins. From the 189 subjects screened in the dal-
PLAQUE trial, 40 were included in this study.
Image acquisition
PET/CT All PET scanners were fully calibrated and corrections
applied for attenuation, isotope decay, dead time, normalization,
sensitivity, scatter and random coincidences. Patients were
instructed to avoid meals rich in carbohydrates starting from
12 h before 18F-FDG injection. Additionally subjects were asked
to abstain from heavy physical activity for 24 h before imaging to
reducemuscle uptake of 18F-FDG.Approximately 30min before
18F-FDG injection, glucose was measured: if fasting blood glu-
cose was higher than 200 mg/dL, imaging was rescheduled,
otherwise patients were injected with 15 mCi (555 MBq) 18F-
FDG, bought commercially from local vendors. After 120min of
FDG circulation time [3–5], a low-dose, non-contrast-enhanced
CTscanwas performed for attenuation correction and anatomical
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coregistration. After aortic imaging for the purpose of the trials,
carotid PET data were acquired in 3-D mode for 15 min using
one bed position with the superior aspect of the field of view
being the internal auditory meatus.
Anatomical MRI Carotid MRI was performed on 1.5-T clin-
ical whole-body systems (SiemensMedical Solutions, Erlang-
en, Germany) in the head-first supine position using a four-
channel carotid array (Machnet, Netherlands) for signal recep-
tion. Sixteen non-overlapping cross-sectional T1-weighted
(echo time, TE, 9 ms; repetition time, TR, 800 ms), T2-
weighted (TE 56 ms; TR 2,000 ms) and proton density-
weighted (PD-weighted; TE 9 ms, TR 2,000 ms) images were
obtained using multislice, fat-saturated 2-D turbo spin echo
(TSE) acquisitions starting at, and extending below, the left
carotid bifurcation as previously described [14, 15]. Dark
blood was obtained using in-flow and out-flow saturation.
Other relevant imaging parameters common to all three ac-
quisitions were: field of view 140×140 mm, matrix size 256×
256, in-plane spatial resolution 0.55×0.55mm, slice thickness
3 mm, interslice gap 0.3 mm, excitation flip angle 90°,
refocusing angle 180°, turbo factor 15, four signal averages.
DCE-MRI DCE-MRI was performed on one selected axial
slice (chosen from the T1-weighted image set, as the slice with
the greatest degree of carotid wall thickening) using a black-
blood, fat-saturated TSE sequence after injection of 0.2 mmol/
kg gadolinium-diethylene triamine pentaacetic acid (Gd-
DTPA, Magnevist; Bayer Schering Pharma) [6]. Black blood
was obtained using a double inversion recovery technique.
Relevant imaging parameters were: TE 5.6 ms, TR 250 ms,
field of view 140×140 mm, matrix size 256×256, in-plane
spatial resolution 0.55×0.55 mm, slice thickness 3 mm, exci-
tation flip angle 90°, refocusing angle 180°, turbo factor 15,
one signal average, 100 measurements.
More details on the PET and MRI acquisition parameters
are provided by Fayad et al. [14, 15]. For the purpose of this
comparison, only data from 4 of the 11 imaging sites passed
our imaging quality control to ensure uniformity between
MRI protocols, vendors and field strength.
Image analysis
A schematic representation of the image analysis is shown in
Fig. 1.
Measurement of 18F-FDG uptake PET/CT images were ana-
lyzed using OsiriX (Geneva, Switzerland; http://www.osirix-
viewer.com/) and in-house software for data handling. Arterial
Fig. 1 Schematic view of image
analysis in common carotid
arteries. Dashed lines represent
acquired PET/CT and MRI axial
slices. Data from all the slices
were used for the whole-vessel
analyses (red dashed line DCE-
MRI slice, orange dashed lines
PET slices surrounding the slice
matched with DCE-MRI included
in the analysis to take into account
possible misregistrations between
the two techniques)
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18F-FDG uptake was measured by drawing circular regions of
interest (ROI) on all PET/CT slices of both common carotid
arteries. ROIs were fitted to the artery wall on each axial slice,
while coronal and sagittal views were used to ensure that
uptake was from the artery. Whole-vessel mean, maximum
and mean of maximum standardized uptake values (SUV)
were recorded. Arterial SUV was normalized to the blood
pool SUV measured from five slices in the jugular vein to
calculate the whole-vessel mean, maximum and mean of
maximum arterial target-to-background ratio (TBR) [5].
SUV and TBR are both well-validated measures of 18F-FDG
uptake. To account for possible misregistration errors between
DCE-MRI and PET/CT data, we recorded mean, maximum
and mean of maximum SUV and TBR across five slices
centered on the slice matching the DCE slice (Fig. 1, approx-
imately 1-cm segment).
Anatomical MRI Inner and outer vessel wall contours were
manually traced by an experienced observer on all slices for
both common carotid arteries using T2-weighted multislice 2-
D TSE images. Mean lumen diameter, vessel diameter, lumen
area, wall area, total vessel area, mean wall thickness, standard
deviation of wall thickness and normalized wall index for each
slice were calculated using a customized software program
(Vessel Mass Software; Leiden University Medical Center,
The Netherlands) as previously described [17], and interfaced
with in-house custom software for data analysis. Whole-vessel
parameters were recorded, as well as single slice values
matched with DCE-MRI acquisition. Plaque components were
classified by an experienced observer by looking simultaneous-
ly at the T1-, T2- and PD-weighted multislice 2-D TSE acqui-
sitions to assess the presence or absence of LRNC, calcification
and intraplaque hemorrhage, as described by Fayad et al. [14,
15]. Plaques were characterized across the whole vessel as well
as on the slice matching with the DCE-MRI acquisition.
DCE-MRI The uptake of contrast agent was evaluated with a
custom-made MATLAB (The MathWorks Inc., Natick, MA)
program [6]. To ensure proper calibration between different
imaging sessions, curves were converted to contrast agent
concentrations using the spoiled gradient echo signal model
[18] and the widely accepted linear relationship between
relaxation rates and concentration. Contrast agent relaxivity
was assumed to be 4.3 mmol−1 s−1 [19]. Kinetic modeling was
performed using a population arterial input function (AIF)
[20] and the model of Tofts et al. with modification [21].
Kinetic parameters vp (fraction of vascular space), K
trans
(wash-in constant from plasma to tissue compartment), v e
(fraction of extravascular extracellular space), and K ep
(wash-out constant from tissue to plasma compartment) were
calculated using standard nonlinear least squares fittings [22]
in MATLAB. The non-model based parameter area under the
concentration curve (AUC) [6, 10–12] was also calculated at
1 min (AUC1) and 2 min (AUC2) after injection of contrast
agent [6] (Fig. 1).
Image coregistration between 18F-FDG PET/CT and DCE-
MRI Anatomical coregistration between the DCE-MRI slice
and the corresponding PET/CT slice was performed using
automated registration of the CT- and PD-weighted
high-resolution MR images using a Leonardo workstation
(Siemens Medical Solutions, Erlangen, Germany). When nec-
essary, manual adjustments were applied to correct for mis-
alignments in the automated registration.
Statistical methods
The main goal of our analysis was to correlate perfusion
metrics by DCE-MRI with plaque inflammation as measured
by 18F-FDG PET/CT. We also assessed the correlation be-
tween: (a) whole-vessel PET/CTand whole-vessel anatomical
MRI variables and (b) single-slice perfusion measures by
DCE-MRI with matching single-slice anatomical MRI vari-
ables. Correlations were calculated using a mixed linear model
with a compound symmetric correlation structure [23],
implemented with PROC MIXED in SAS v. 9.2. All data
were natural log-transformed to achieve normality. This mod-
el accounted for the correlation between measurements of the
same variable within each of the 40 patients in the study. The
95 % confidence interval for each correlation coefficient was
constructed using the bootstrap method [24], in which 1,000
bootstrap samples of size n =40 were generated. Each sample
consisted of 40 subjects being sampled with replacement from
the complete list of 40 subjects; for each bootstrap sample,
PROC MIXED calculated a correlation coefficient from the
mixed model. The distribution of these 1,000 correlation
coefficients provided estimates of the 2.5th and the 97.5th
percentiles as the upper and lower confidence limits for the
initial point estimate. When the 95 % confidence interval did
not include zero (both limits had the same sign, positive or
negative) the correlation was considered significantly differ-
ent from zero at the 5 % level of significance. To adjust for the
multiple statistical tests performed, Bonferroni correction was
also applied to the comparisons presented in each table in the
Results section. The p value of 0.05 used to establish signif-
icance was divided by the number of comparisons considered
in each table (36 for Tables 2 and 5; 24 for Table 4). Therefore,
p <0.001 was required for the comparisons in Tables 2 and 5,
and p <0.02 was required for the comparisons in Table 4 to
reach statistical significance. The results are presented with
and without Bonferroni correction. If correlation coefficients
were less than 0.3, the correlation was considered weak; if
higher or equal to 0.3 but lower than 0.7, the correlation was
considered moderate; if higher or equal to 0.7, the correlation
was considered strong.
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Results
Patient population
The mean age of the population was 64.2 years, and most
were men (78.8 %). Baseline lipid biomarkers revealed aver-
age total cholesterol of 146.8 mg/dL, with average LDL-C
being 74.8 mg/dL and high-density lipoprotein cholesterol
(HDL-C) being 45.8 mg/dL. Baseline demographics are
presented in Table 1.
Relationship between 18F-FDG PET/CT and DCE-MRI data
The relationship between DCE-MRI and PET variables was
analyzed using a mixed linear model (Table 2). Comparing
arterial FDG uptake by PET/CTand DCE-MRI measurements
without Bonferroni correction, the non-model-based parame-
ter AUC1 showed a weak significant inverse correlation with
mean SUV, with a correlation coefficient −0.23. The parame-
ter AUC2 exhibited a weak significant inverse correlation
with maximum SUV (correlation coefficient −0.21). The
model-based parameter K trans, believed to represent a mixture
of flow and permeability, exhibited weak significant inverse
correlations with maximum SUV (correlation coefficient
−0.22), mean TBR (correlation coefficient −0.24; Fig. 2a)
and mean of maximum TBR (correlation coefficient −0.22).
The model-based parameter vp, expressing the fractional plas-
ma volume, showed moderate inverse significant correlations
with mean SUV (correlation coefficient −0.41) and mean of
maximum SUV (correlation coefficient −0.32). The model-
based parameter K ep (backflow constant from tissue to
plasma) showed weak inverse significant correlations with
mean SUV and TBR (correlation coefficients −0.28 and
−0.23; Fig. 2b) and mean of maximum SUVand TBR (corre-
lation coefficients −0.24 and −0.20). The model-based param-
eter ve did not show any significant correlations with SUVor
TBR values. No significant correlations were found when
using Bonferroni correction. Figure 3 shows PET/CT images
and DCE-MRI uptake curves from two patients representative
of our sample. The PET/CT images and Gd-DTPA uptake data
are from a patient with low 18F-FDG uptake by PET/CT but
high Gd-DTPA uptake byDCE-MRI (Fig. 3a–c), and a patient
with high 18F-FDG and low Gd-DTPA uptake (Fig. 3d–f).
Correlation between anatomical MRI and PET/CT data
Table 3 shows the results of analysis of whole-vessel anatom-
ical MRI data. The dataset was composed mainly of non-
complex carotid atherosclerotic plaques, with calcification be-
ing identified in only 15.1 % and LRNC in 36.4 % of the
lesions. Intraplaque hemorrhage was absent from the entire
cohort of subjects in this substudy. Among the slices chosen
for DCE-MRI, 6.1 % showed calcification and 18.2 % re-
vealed LRNC. Mean wall thickness averaged across the whole
vessel calculated from anatomical MRI data showed a moder-
ate but significant positive correlation with the average whole-
vessel TBR, with a correlation coefficient 0.39 (Table 4) with-
out Bonferroni correction. No significant correlations were
found between any of the PET variables and plaque composi-
tion byMRI (data not shown). No significant correlations were
found when using Bonferroni correction.
Correlation between anatomical MRI and DCE-MRI data
Analysis of high-resolution anatomicalMRI data revealed that
average and standard deviation of wall thickness weakly
positively correlated with the DCE-MRI parameter K ep (cor-
relation coefficients 0.21 and 0.25, respectively) when not
using Bonferroni correction. No significant correlations were
found between DCE-MRI metrics and plaque composition by
MRI (data not shown). No significant correlations were found
when using Bonferroni correction.
Discussion
The main goal of this study was to investigate the relationship
between 18F-FDG PET/CT and DCE-MRI data from the
carotid arteries of 40 patients with CHD or CHD risk equiv-
alent recruited as part of the dal-PLAQUE study [14, 15].
These techniques offer a quantitative read-out for plaque
macrophages [4] and neovessels, respectively [6, 7], two of
the hallmarks of plaque vulnerability. We found a significant
weak inverse relationship between the results from the two
Table 1 Baseline patient characteristics (n =33)
Characteristic Value
Age (years), mean (SD) 64 (8.0)
Male sex, n (%) 26 (78.8)
Body mass index (kg/m2), mean (SD) 29 (5.1)
Medical history, n (%)
Type II diabetes 10 (30.3)
Hypertension 20 (60.6)
CHD 28 (84.8)
Abdominal aortic aneurysm 1 (3.0)
Symptomatic carotid disease 3 (9.1)
Peripheral arterial disease 2 (6.1)
Smoking 4 (12.1)
Lipids (mg/dL), mean (SD)
Total cholesterol 146.8 (29.0)
LDL-C 74.8 (19.8)
HDL-C 45.8 (14.7)
Triglycerides 130.7 (64.1)
High-sensitivity C-reactive protein 2.6 (3.5)
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techniques. As secondary endpoints, we explored the
relationships between non-contrast-enhanced anatomical MRI
data and data from both DCE-MRI and FDG PET/CT. The
anatomical MRI data showed a significant weak positive
correlation with the DCE-MRI data and a significant weak
inverse correlation with the PET/CT data.
Previous studies have investigated the relationship between
anatomical MRI and 18F-FDG PET/CT data and found higher
FDG uptake in complex lesions, but no or only a weak
correlation with plaque wall thickness. Silvera et al. found
higher FDG uptake in lipid-based compared to collagen-rich
or calcified plaques using TBR [25]. Additionally (only in the
LRNC group), they found a significant variation in TBR
according to the median of the vessel wall thickness. On the
contrary, Kwee et al. [26] found higher FDG uptake measured
as SUV in fibrous, but not lipid-rich, plaques. Additionally,
they found a correlation between SUV and vessel wall vol-
ume. In this study, we confirmed a significant relationship
between average whole vessel TBR by PET/CT and average
wall thickness by anatomical MRI, but fail to demonstrate a
correlation between FDG uptake and plaque composition
(Table 4). This difference from the two studies mentioned
above may be due to the patient population and nature of the
lesions (more complex in other studies, versus non-complex
in the present study). Additionally, we demonstrates weak but
significant correlations between anatomical MRI measures
such as average wall area and average and standard deviation
of wall thickness and the DCE-MRI metric K ep, while no
correlation was found with plaque composition (Table 5).
Recently, Cyran et al. [27] studied the relationship between
18F-FDG PET/CT and DCE-MRI results in patients with
supraaortic arteritis, and found a positive significant correla-
tion between mean arterial TBR and extraction fraction of
MRI contrast agent. Taqueti et al. [28] also found a positive
significant correlation between FDG uptake measured as TBR
and K trans by DCE-MRI and neovessels by histology in pa-
tients with severe carotid stenosis. In this study we found a
weak but significant inverse correlation between model-based
and non-model-based DCE-MRI metrics and SUV and TBR
by PET/CT. There may be several reasons for this difference
in findings. Firstly, it must be noted that the patient popula-
tions in the two studies were very different: while Taqueti et al.
Fig. 2 Correlation between
DCE-MRI parameters and mean
TBR by PET/CT in the carotid
arteries of subjects with CHD or
CHD risk equivalent. a
Correlation between K trans by
DCE-MRI and mean TBR by
PET/CT. b Correlation between
Kep by DCE-MRI and mean TBR
by PET/CT. Black dotted line
regression line
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[28] studied subjects presenting with a high degree of carotid
stenosis, in this study we investigated subjects with non-
complex atherosclerotic lesions (Table 3). Differences in med-
ication usage between the population investigated in this study
and other studies may also act as a confounding factor. Addi-
tionally, while it is known that PET/CT and DCE-MRI pro-
vide an indication of the extent of plaque macrophages and
neovessels, their metrics may not exclusively reflect these
histological features. For example, contrast agent extravasa-
tion in DCE-MRI depends not only on neovessel density and
permeability, but also on the fractional extravascular extracel-
lular space available for contrast agent distribution [21].
Alternatively, it is possible that plaque macrophage content
and neovascularization (and therefore 18F-FDG uptake on
PET and Gd-DTPA uptake on DCE-MRI) may exhibit differ-
ent relationships with each other depending on the stage of the
plaque that is being imaged.
Another potential explanation for our findings resides in
the interplay between neovascularization, hypoxia and inflam-
mation [29]. It is relatively well established that hypoxia and
Fig. 3 18F-FDG PET/CT images and Gd-DTPA uptake data by DCE-
MRI from representative patients showing the relationship between Gd-
DPTA uptake and 18F-FDG uptake. a–c Patient with low arterial FDG
uptake by PET/CT but high Gd-DTPA uptake by DCE-MRI. d–f Patient
with high arterial FDG uptake by PET/CT but low Gd-DTPA uptake by
DCE-MRI. a , d FDG PET image overlain on CT image (blue circles
common carotid artery, red circles jugular vein). b , e T1-W MRI image
after contrast agent administration. c , f Kinetic modeling of Gd-DTPA
uptake by DCE-MRI (blue dots experimental data, red line model fit).
SM skeletal muscle, L vessel lumen
Table 2 Correlation between DCE-MRI and slice-matched 18F-FDG
PET/CT parameters (n =40)
PET/CT parameters DCE-MRI parameters
AUC1 AUC2 K trans ve Kep vp
SUV_Mean −0.23 −0.22 −0.25 0.02 −0.28 −0.41
SUV_Max −0.18 −0.21 −0.22 −0.04 −0.20 −0.25
SUV_MeanofMax −0.20 −0.20 −0.22 0.02 −0.24 −0.32
TBR_Mean −0.23 −0.20 −0.24 −0.02 −0.23 −0.30
TBR_Max −0.10 −0.11 −0.15 −0.14 −0.04 −0.29
TBR_MeanofMax −0.20 −0.19 −0.22 −0.04 −0.20 −0.29
Bold type indicates a significant correlation without Bonferroni correc-
tion (P<0.05)
Table 3 Non-contrast-enhanced MRI analysis
Measure (mean and standard deviation) Whole vessel
(n =33)
DCE-MRI
slice (n=40)
Average total vessel area (cm2), mean
(SD)
0.61 (0.20) 0.60 (0.13)
Average wall area (cm2), mean (SD) 0.28 (0.11) 0.24 (0.06)
Average lumen area (cm2), mean (SD) 0.32 (0.11) 0.36 (0.08)
Average mean wall thickness (mm),
mean (SD)
1.15 (0.24) 0.97 (0.20)
Average standard deviation of wall
thickness (mm), mean (SD)
0.27 (0.19) 0.20 (0.11)
Average normalized wall indexa, mean
(SD)
0.46 (0.07) 0.40 (0.06)
Calcification, n (%) 5 (15.1) 2 (6.1)
Hemorrhage, n (%) 0 (0) 0 (0)
Lipid rich necrotic core, n (%) 12 (36.4) 6 (18.2)
aWall area/total vessel area based on the average of the right and left
carotid arteries
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inflammation are intertwined at the molecular, cellular and
clinical levels [30]. Hypoxic conditions are known to develop
in atherosclerotic plaques as a result of smooth muscle cell
proliferation in the tunica intima, subsequent wall thickening,
and increased oxygen consumption bymacrophages and foam
cells [31–33]. Hypoxia induces increased glycolysis [34, 35]
in macrophages (hence increased FDG uptake). In addition to
increasing macrophage glycolysis, hypoxia is known to in-
crease macrophage activation, phagocytosis [36] and tumor
necrosis factor production [37]. This hypothesis offers a pos-
sible explanation for our findings, where higher FDG uptake
was inversely correlated with plaque neovascularization
shown by DCE-MRI. It is therefore possible to envision a
scenario where the hypoxia-driven inflammatory response
may precede an increase in plaque neovascularization by
neoangiogenesis [38]. This hypothesis has been corroborated
by more recent in vivo findings by Pedersen et al. [39], which
show the relationship between SUV and expression of genes
of plaque vulnerability and neoangiogenesis in human carotid
specimens. Pedersen et al. found a significant but negative
correlation between CD34, a histological marker of
microvessel density, and both SUV by 18F-FDG-PET and
CD68, a histological marker of macrophages. No correlation
was found between SUV and markers of neoangiogenesis
(vascular endothelial growth factor). The authors concluded
that 18F-FDG uptake inversely reflects microvessel density,
but not neoangiogenesis in human atherosclerotic plaques.
Since DCE-MRI metrics are known to reflect plaque
neovessel content, this may explain the higher substantial
18F-FDG uptake in areas of low uptake of Gd-DTPA on
DCE-MRI and vice versa.
Together with other studies, our findings suggest that 18F-
FDG PET and DCE-MRI may offer complementary, non-
overlapping information about vascular inflammation and
neoangiogenesis. This suggests that these two techniques may
be used in combination in future clinical practice for accurate
staging and risk stratification of atherosclerotic plaques. How-
ever, a more thorough investigation of these twomodalities and
their underlying histological correlates at the different stages of
plaque progression is needed before their clinical use.
Study limitations
Possible limitations of the study are as follows. Firstly, the
sample size was relatively small (40 subjects) and comparison
of the imaging findings with a histological gold standard was
not possible. Due to the small sample size, subgroup analyses
of symptomatic versus asymptomatic subjects were also not
possible. Secondly, DCE-MRI achieved limited single-slice
coverage to maintain sufficiently fast temporal resolution
(4.8 s) together with a high spatial resolution (0.5×0.5 mm)
for the reliable estimation of contrast agent uptake and good
characterization of plaque composition. This required careful
matching of DCE-MRI slices with the corresponding anatom-
ical MRI and PET/CT images, which may be affected by
misregistration. The development of novel technologies such
as integrated PET/MRI scanners will, in the future, allow these
studies to be performed simultaneously, naturally providing
coregistered PET and MRI images, and therefore eliminating
this issue [40]. PET imaging has quite poor spatial resolution
for imaging small structures, such as atherosclerotic vessel
walls. However, this modality has been used successfully in
combination with CT, which provides anatomical details and
attenuation correction, to quantify inflammation in atheroscle-
rotic plaques [4]. PET/MRI may allow the application of
partial volume correction techniques to help image small struc-
tures, such as the vasculature, with increased accuracy [41].
A black-blood sequence was chosen for DCE-MRI acqui-
sition to allow better delineation of these non-complex ath-
erosclerotic lesions from the vessel lumen during dynamic
scanning. Despite allowing clear visualization of the arterial
vessel wall by suppressing the blood signal, black-blood
imaging does not allow sampling a per-patient AIF for kinetic
Table 4 Correlation between anatomicalMRI andwhole-vessel PET/CT
data
Average
SUV
Maximum
SUV
Average
TBR
Maximum
TBR
Average total vessel area
(cm2)
0.04 0.00 0.12 0.08
Average wall area (cm2) 0.05 0.00 0.29 0.23
Average lumen area (cm2) 0.03 0.01 −0.09 −0.10
Average mean wall
thickness (mm)
0.05 0.01 0.39 0.33
Average standard deviation
of wall thickness (mm)
0.01 −0.03 0.30 0.24
Average normalized wall
index
0.04 0.01 0.33 0.29
Bold type indicates a significant correlation without Bonferroni correc-
tion (P<0.05)
Table 5 Correlation between anatomical MRI and DCE-MRI data
AUC1 AUC2 K trans ve Kep vp
Average total vessel area
(cm2)
0.10 0.11 0.09 0.06 0.06 0.12
Average wall area (cm2) 0.14 0.17 0.15 0.00 0.16 0.09
Average lumen area
(cm2)
0.08 0.07 0.04 0.09 −0.02 0.10
Average mean wall
thickness (mm)
0.11 0.14 0.16 −0.05 0.21 0.07
Average standard
deviation of wall
thickness (mm)
0.08 0.08 0.07 −0.21 0.25 −0.16
Average normalized wall
index
0.07 0.10 0.15 −0.11 0.24 0.00
Bold type indicates a significant correlation without Bonferroni correc-
tion (P<0.05)
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modeling. A population-derived AIF [20] was used for anal-
ysis, which may have introduced inaccuracies into the calcu-
lation of model-based parameters. Finally, no significant cor-
relations were found when using Bonferroni correction. While
Bonferroni correction is applied when multiple statistical tests
are performed to avoid type 1 errors (false positives), it is a
rather conservative approach which does increase the chance
of type 2 errors (false negatives). While some of the correla-
tions reported without Bonferroni correction are likely to have
been false positives, in this case the correction demands p <
0.001 (Tables 2 and 5) and p <0.002 (Table 4) to reach
significance. As this may conceivably have led to some false
negatives, both corrected and uncorrected results are reported.
Conclusion
In conclusion, in this study we found a significant inverse
relationship between non-model and model-based perfusion
indices by DCE-MRI (indices of neovascularization) and
SUVand TBR by PET/CT (markers of macrophage content).
This finding, in combination with other findings in the litera-
ture, suggests that there may be a complex relationship be-
tween plaque inflammation and neovascularization, and that
18F-FDG PET and DCE-MRI images have complex histolog-
ical correlates, whose relationship may change during plaque
progression. The combination of PET/CT and DCE-MRI
imaging may prove to be a useful tool in drug development
for proof of concept of new therapies.
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